epigallocatechin gallate has been researched along with Age-Related Macular Degeneration in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Blasiak, J; Chojnacki, C; Chojnacki, J; Fila, M; Kaarniranta, K; Pawlowska, E; Szczepanska, J | 1 |
Du, J; Du, S; Gu, Y; Guo, Y; Song, E; Sun, X; Tu, Y; Wang, Y; Xie, L; Xu, J; Xu, X; Zhao, Q; Zhu, M | 1 |
Harini, L; Kannan, VR; Karthikeyan, B; Kathiresan, T; Krishnakumar, V; Sundar, K | 1 |
1 review(s) available for epigallocatechin gallate and Age-Related Macular Degeneration
Article | Year |
---|---|
Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration.
Topics: Humans; Macular Degeneration; Retina; Tea; Vascular Endothelial Growth Factor A | 2023 |
2 other study(ies) available for epigallocatechin gallate and Age-Related Macular Degeneration
Article | Year |
---|---|
Prodrug of epigallocatechin-3-gallate alleviates choroidal neovascularization via down-regulating HIF-1α/VEGF/VEGFR2 pathway and M1 type macrophage/microglia polarization.
Topics: Animals; Catechin; Cell Polarity; Cells, Cultured; Choroidal Neovascularization; Down-Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Macular Degeneration; Male; Mice; Mice, Inbred C57BL; Microglia; Prodrugs; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration.
Topics: Animals; Antioxidants; Apoptosis; Calcium; Calcium Signaling; Catechin; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Humans; Hydrogen Peroxide; Macular Degeneration; Mice; Mitochondria; Oxidative Stress; Reactive Oxygen Species; Thapsigargin; Unfolded Protein Response | 2017 |